Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.
Asiimwe IG, Zhang EJ, Osanlou R, Krause A, Dillon C, Suarez-Kurtz G, Zhang H, Perini JA, Renta JY, Duconge J, Cavallari LH, Marcatto LR, Beasly MT, Perera MA, Limdi NA, Santos PCJL, Kimmel SE, Lubitz SA, Scott SA, Kawai VK, Jorgensen AL, Pirmohamed M. Asiimwe IG, et al. Among authors: osanlou r. Clin Pharmacol Ther. 2020 Jun;107(6):1420-1433. doi: 10.1002/cpt.1755. Epub 2020 Jan 28. Clin Pharmacol Ther. 2020. PMID: 31869433 Free PMC article.
Warfarin dosing algorithms: A systematic review.
Asiimwe IG, Zhang EJ, Osanlou R, Jorgensen AL, Pirmohamed M. Asiimwe IG, et al. Among authors: osanlou r. Br J Clin Pharmacol. 2021 Apr;87(4):1717-1729. doi: 10.1111/bcp.14608. Epub 2020 Nov 18. Br J Clin Pharmacol. 2021. PMID: 33080066 Free PMC article. Review.
Who clerks-in medical patients?
Watters C, Osanlou R, Osanlou O, Clark K, Constable C. Watters C, et al. Among authors: osanlou r, osanlou o. Clin Med (Lond). 2017 Jun;17(Suppl 3):s17. doi: 10.7861/clinmedicine.17-3-s17. Clin Med (Lond). 2017. PMID: 30958779 Free PMC article. No abstract available.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Lambe T, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Munro APS, et al. Among authors: osanlou r, osanlou o. Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2. Lancet. 2021. PMID: 34863358 Free PMC article. Clinical Trial.
21 results